Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin + AG Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
NCT06825546Phase 2Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of Icaritin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Sir Run-Run Shaw Hospital. Started Apr 2025; status: recruiting.
02
Drugs
Icaritin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06825546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825546.